Table 6 Susceptibility of E. coli and P. aeruginosa isolates to commonly used antibiotics.

TNICU

E. coli

ampicillin

42/83 (51)

40/76 (53)

0.80

cefazolin

70/83 (84)

61/76 (80)

0.50

cefotaxime

72/83 (87)

64/76 (84)

0.65

ciprofloxacin

68/83 (82)

60/76 (79)

0.64

TMP-SMX

66/83 (80)

61/76 (80)

0.91

piperacillin-tazobactam

70/83 (84)

63/76 (83)

0.81

imipenem

85/85 (100)

76/77 (99)

0.48^a

gentamicin

77/83 (93)

70/76 (92)

0.87

tobramycin

76/83 (92)

70/76 (92)

0.90

P. aeruginosa

ceftazidime

27/30 (90)

22/23 (96)

0.62^a

ciprofloxacin

27/30 (90)

18/23 (78)

0.27^a

piperacillin-tazobactam

27/30 (90)

22/23 (96)

0.62^a

imipenem

30/30 (100)

20/23 (87)

0.076^a

gentamicin

28/30 (93)

23/23 (100)

0.50^a

tobramycin

30/30 (100)

23/23 (100)

-

MSICU

E. coli

ampicillin

37/95 (39)

30/81 (37)

0.79

cefazolin

65/95 (68)

59/81 (73)

0.52

cefotaxime

73/95 (77)

64/81 (79)

0.73

ciprofloxacin

46/95 (48)

49/81 (60)

0.11

TMP-SMX

58/95 (61)

43/81 (53)

0.29

piperacillin-tazobactam

64/95 (67)

59/80 (74)

0.36

imipenem

93/95 (98)

81/82 (99)

1.00^a

gentamicin

76/95 (80)

73/81 (90)

0.063

tobramycin

72/95 (76)

72/81 (89)

0.025

P. aeruginosa

ceftazidime

50/64 (78)

42/58 (72)

0.46

ciprofloxacin

58/64 (91)

41/58 (71)

0.0049

piperacillin-tazobactam

50/64 (78)

40/58 (69)

0.25

imipenem

51/64 (80)

41/58 (71)

0.25

gentamicin

58/64 (91)

48/58 (83)

0.20

tobramycin

62/64 (97)

56/58 (97)

1.00^a